Author

C. Antczak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:C. elegans· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Organism:Drosophila· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Hadjikyriacou· 1 shared B. Nyfeler· 1 shared C. D. Driscoll· 1 shared D. E. Nunes· 1 shared E. M. Oberlick· 1 shared E. O. Perlstein· 1 shared F. S. Sam· 1 shared F. Sigoillot· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. Hadjikyriacou

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GATA1 knockout in human pluripotent stem cells generates enhanced neutrophils to investigate extracellular trap formation

T. C. Harper, E. M. Oberlick, T. J. Smith, D. E. Nunes, M. A. Bray, S. Park, C. D. Driscoll, S. F. Mowbray, C. Antczak

This study generates GATA1 knockout human pluripotent stem cell-derived neutrophils that form extracellular traps, improving models for studying NET formation and drug screening.

bioRxiv · Feb 8, 2023 · PreprintImmunology

Multi-Species Phenotypic Screening across Disease Models of Mucolipidosis Type IV

A. Hadjikyriacou, S. Iyer, J. D. Mast, N. DiPrimio, J. Concannon, J. Ketterman, F. Sigoillot, T. P. Rodriguez, F. S. Sam, H. Tsang, M. Prangley, J. Bilen, K. Murthy, T. A. Hartl, C. Antczak, , S. M. Canham

The paper screens a compound library across invertebrate and human models of mucolipidosis IV to identify conserved disease modifiers, finding cyclin-dependent kinase inhibition as a potential therapeutic strategy.

bioRxiv · Mar 5, 2021 · PreprintCell Biology